Dr. Jian Han
Chairman of the Board since 2009
Dr. Jian Han is the founder of iCubate. Currently, he serves as Chairman of the Board and as the Corporation’s President and Chief Scientific Officer. Dr. Han obtained his M.D. from Suzhou Medical College in China and his Ph.D. in Molecular Genetics from the University of Alabama at Birmingham (UAB). He became an Assistant Professor at UAB in 1994 and served as Clinical Molecular Laboratory Director. He is a board-certified clinical molecular geneticist. In 1996, he started a biotech company, Genaco Biomedical Products, Inc. Genaco developed a multiplex molecular assay for profiling pathogens associated with respiratory infections. After a series of successful development and validation studies, Genaco’s core technology, tem-PCR on the Luminex platform gained market recognition and ultimately won the Frost & Sullivan Technology Innovation and Leadership award and Wall Street Journal Technology Innovation award. In 2006, Qiagen acquired Genaco. Following the sale to Qiagen, Dr. Han joined the HudsonAlpha Institute for Biotechnology. At HudsonAlpha, he developed the next generation multiplex PCR technology, the arm-PCR method, the core technology for iCubate. He retained many of the talented employees from Genaco and recruited exceptional engineers to develop the iCubate instrument platform.
Dr. Chiung-Mei Lu
Member of the Board since 2009
Dr. Chiung-Mei Lu is a board member of iCubate. Dr. Lu obtained her Bachelor of Science in Nutritional Science from TaiPei Medical University and received her Ph.D. from UAB (1991) in Neuroscience. After postdoctoral training at UAB, she joined Research Genetics to lead their microarray development team in charge of customer support and training. After Research Genetics was acquired by Invitrogen, Dr. Lu joined Genaco to serve as COO. Under Dr. Lu’s management, Genaco excelled with limited funding and resources. She directed a team to work with the FDA consultants to build Quality Systems for the company and helped prioritize research and development projects and coordinate marketing efforts.
Ms. Sue Whitehead
Member of the Board since 2014
Ms. Sue Whitehead is a board member of iCubate. Ms. Whitehead received her Bachelor of Science in Computer Science from Texas State University. Ms. Whitehead serves on the board of Diatherix Laboratories, a provider of clinical laboratory services for the detection of infectious diseases. Ms. Whitehead also serves on the HudsonAlpha Foundation Board, which helps ensure long-term growth, sustainability and security for HudsonAlpha’s future of providing improvements for human health and quality of life. A seasoned investor in life sciences start-up companies, Ms. Whitehead provides near and long term financial strategic counsel for the company.
Mr. Tom Young
Member of the Board since 2009 Mr. Tom Young is a board member of iCubate. Mr. Young is the founder and Chief Executive Officer of Kord Technologies, a consulting and technical services company with various Department of Defense and NASA customers and contracts. Prior to founding Kord, Mr. Young was the Chief Executive Officer of Qualitest/Vintage Pharmaceuticals, one of the nation’s largest drug companies. Prior to joining Qualitest, he served as Executive Vice-President at Intergraph Corporation, a Huntsville-based software and services company. Additionally, Mr. Young was Chief of Staff for U.S. Senator Richard C. Shelby (R-AL).
Mr. Sijie Justin Zhang
Member of the Board since 2018
Mr. Sijie Justin Zhang is a board member of iCubate. Mr. Zhang currently serves as Business Development Executive of Guangzhou Wondfo Biotech Co. Ltd, a fast growing and leading diagnostic company in China. Mr. Zhang received his MSc. in Biochemistry/Molecular Biology from Sun Yat-Sen University. He has been working in the diagnostic field for years, with experience ranging from global marketing to innovative technology identification, collaboration and transfer. Mr. Zhang acted in a major role in the collaboration and investment projects between Wondfo and Atlas Genetics (now Binx), iCubate and Biocartis.
Mr. Carter Wells
Chief Executive Officer since 2010
Mr. Carter Wells is the Chief Executive Officer of iCubate. Mr. Wells provides the overall leadership to the dedicated team and strategic vision to promote the growth of the company. Mr. Wells maintains strong relationships with iCubate’s board of directors and shareholders. Mr. Wells provides the operational direction to the talented group of biologists, chemists, engineers, quality assurance and regulatory specialists, software developers and manufacturing technicians along with the internal and external financial groups and a cadre of consultants and advisors. Mr. Wells is responsible for raising capital and maintaining the company’s financial health. He manages the company’s marketing and communications efforts to most effectively promote the company. He is responsible for identifying and developing leads for revenue and building relationships for strategic partnerships. Under Mr. Wells’ leadership, the iCubate team has achieved FDA clearance, CE marking and executed international agreements. Mr. Wells is a graduate of Auburn University.
Mr. Wells worked in various political and governmental roles in the southeast and midwest. Mr. Wells served as Chief of Staff for United States Representative Robert E. “Bud” Cramer from 2001 until 2009. In 2009, Mr. Wells joined the HudsonAlpha Institute for Biotechnology and holds the position of Vice President of Economic Development. Mr. Wells serves on the board of the Business Council of Alabama. He is a past board chair of BioAlabama, a statewide organization representing Alabama’s biosciences related industries, research institutes and academia; former board member of the startup incubator BizTech and the Huntsville-Madison County Public Library.